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Highlights 
 This is the first meta-analysis to investigate the relationship between vitamin D and diabetes 
in older adults. 
 The meta-analysis included 28,258 older adults, followed for over 7.7 years.  
 Lower levels of vitamin D were associated with a 31% higher risk of future diabetes  
 After adjusting for 11 confounders, the risk of diabetes was 16% higher among older adults 
with low levels of vitamin D.  
 
 
ABSTRACT 
Low serum levels of 25 hydroxyvitamin D (25OHD) (hypovitaminosis D) is common in older 
adults and associated with several negative outcomes. The association between hypovitaminosis D 
and diabetes in older adults is equivocal, however. We conducted a meta-analysis investigating if 
hypovitaminosis D is associated with diabetes in prospective studies among older participants. Two 
investigators systematically searched major electronic databases, from inception until 10/07/2016. 
The cumulative incidence of diabetes among groups was estimated according to serum 25OHD 
levels. Random effect models were used to assess the association between hypovitaminosis D and 
diabetes at follow-up. From 4,268 non-duplicate hits, 9 studies were included; these followed 
28,258 participants with a mean age of 67.7 years for a median of 7.7 years. Compared with higher 
levels of 25OHD, lower levels of 25OHD were associated with a higher risk of developing diabetes 
(6 studies; n= 13,563; RR=1.31; 95% CI: 1.11-1.54; I2=37%). The findings remained significant 
after adjusting for a median of 11 potential confounders in all the studies available (9 studies; 
n=28,258; RR=1.17; 95% CI: 1.03-1.33; p=0.02; I2=0%). In conclusion, our data suggest that 
hypovitaminosis D is associated with an elevated risk of future diabetes in older people.  Future 
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longitudinal studies are required and should seek to confirm these findings and explore potential 
pathophysiological underpinnings.   
 
Keywords: vitamin D; hypovitaminosis D, diabetes; aged; meta-analysis. 
 
 
INTRODUCTION 
Type two diabetes is one of the most prevalent and disabling conditions in older people.1 More than 
40% of all cases of diabetes are diagnosed in older adults (aged > 60 years) and the number of older 
people with diabetes is expected to dramatically increase in the next 20 years.2 Diabetes is 
associated with a wide range of adverse outcomes such as pain, lower limb amputation, increased 
healthcare costs3, falls4 and cognitive decline.5 Although treatments for diabetes have improved, the 
prevention of this condition is of importance. Several potential reversible/modifiable risk factors for 
diabetes (including obesity, sedentary lifestyle, high blood pressure and blood cholesterol levels) 
are common targets for the prevention of diabetes.6 However, successful treatment of these risk 
factors has been mixed, with minimal data specifically in older adults7, suggesting there may be 
other potential risk factors that could be treatment targets.   
 
Low vitamin D levels are a potential and easy reversible target for diabetes in older adults. 
Hypovitaminosis D (usually defined as low circulating serum 25 hydroxyvitamin D [25OHD] 
levels) is a common condition in older people.8–10 A number of cross-sectional and case-control 
studies in older adults have reported there is not a significant association between hypovitaminosis 
D and the presence of diabetes, particularly after adjusting the analyses for the presence of some 
potential confounders such as obesity.11–14 In contrast to younger  populations, the depletion of 
susceptible effects might play an important part in the lack of the association between 
hypovitaminosis D and diabetes.15 People with low 25OHD levels in old age may be less prone to 
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the health hazards relating to hypovitaminosis D than those with low 25OHD levels who developed 
diabetes when they were younger.15 However, a large meta-analysis involving 21 prospective 
studies and 76,220 participants, found that having higher serum 25OHD levels protected against the 
onset of diabetes.16 Unfortunately, this meta-analysis included only three studies concerning older 
people, and all these studies reported a non-significant association between baseline serum 25OHD 
status and incident diabetes.16  
Understanding whether hypovitaminosis D is associated with the future onset of diabetes in older 
adults is of importance, due to the high presence of this condition and since the reversibility of this 
condition is potentially very easy to address. Given this background, we conducted a systematic 
review and meta-analysis investigating whether low serum 25OHD (hypovitaminosis D) can predict 
the onset of diabetes in prospective studies among older adults.   
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METHODS 
This systematic review was conducted according to the Strengthening the Reporting of 
Observational Studies in Epidemiology [STROBE] criteria17 and the recommendations in the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] statement.18 
 
Search strategy 
Two independent authors (NV, MS) searched for longitudinal studies considering serum 25OHD 
and diabetes in older people. Major databases (PubMed, EMBASE, SCOPUS) were searched from 
inception until 10th July 2016, without language restrictions. The search strategy used in Pubmed 
was: (vitamin D OR 25-hydroxy vitamin D OR calcidiol OR calcitriol OR calcifediol) AND 
(insulin OR glucose OR beta-cell function OR diabetes*) AND (old OR elderly OR older OR aged) 
A similar search (adapted to the requirements of each database) was conducted in the other 
databases.   
 
Eligibility criteria and study selection 
Articles were eligible if: (1) were longitudinal prospective studies; (2) assessed serum 25OHD as 
indicator of vitamin D status, since it seems the best indicator for vitamin D status 19; (3) included 
only older people, as mean age of the population > 60 years; (4) reported a diagnosis of diabetes at 
follow-up using self-reported data, medical/hospital records, or at least one criterion suggested by 
the American Diabetes Association20 (i.e. fasting plasma glucose (FPG) > 126 mg/dl, glycosylated 
hemoglobin (HbA1c) >6.5% or use of anti-diabetic medications). Studies were excluded if they: (1) 
had a cross-sectional design (2) assessed vitamin D status with methods other than serum 25OHD 
(e.g. dietary vitamin D); (3) included only sub-clinical estimates of diabetes (e.g. changes in fasting 
plasma glucose). 
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References of included articles included were hand-searched to identify additional, potentially 
relevant publications. Conference abstracts were also considered, and in such instances we 
contacted the corresponding authors to acquire the data to enable inclusion.  
 
Data extraction 
Two authors (AB, PL) independently recorded data extracted from the selected studies into a 
standardized Microsoft Excel spreadsheet. Any disagreement was resolved by consensus with a 
third author (BS). The following information was extracted for each study: i) study characteristics 
(e.g. sample size, demographics, country in which the study was performed); ii) study setting; iii) 
number of diabetic people during follow-up; iv) follow-up (in years); v) serum 25OHD levels and 
methods of assessment of 25OHD; vi) diagnostic criteria used for the diagnosis of diabetes; vii) 
number and type of covariates used in the multivariate analyses. 
If more than two categories for serum 25OHD were included, we defined as low the lowest quantile 
and used the highest one as the reference group.   
 
Assessment of study quality 
Study quality was assessed by two investigators (MS, GB), while another one was available for 
mediation (NV). The Newcastle-Ottawa Scale (NOS)21 was used to assess study quality. The NOS 
assigns a maximum of 9 points based on three quality parameters: selection, comparability, and 
outcome.21   
  
Statistical analysis 
A random effects meta-analysis was undertaken using Comprehensive Meta-Analysis (CMA) 
version 3 to account for the anticipated heterogeneity.22  In the primary analyses, pooled RRs and 
95% CI (including the number of incident cases of diabetes in low serum 25OHD vs. higher values) 
were calculated to synthesize data. In the secondary analyses, we included the HR/OR adjusted for 
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the highest number of covariates available for each study and analyzed together using fully-adjusted 
RRs.  
 
Study heterogeneity was assessed using the chi-squared and I-squared statistics, assuming that a 
p<0.05 for the former and a value ≥50% for the latter indicated a significant heterogeneity.23 
Whenever significant heterogeneity existed and ≥4 studies were available, a meta-regression 
analysis was pre-planned taking as potential moderators: continent in which the study was 
performed, study setting (community vs. others), follow-up (as continuous, in years), diagnostic 
criteria used for the diagnosis of diabetes (self-reported vs. others), and number of covariates.  
 
Publication bias was assessed by visually inspection of funnel plots and using the Egger bias test.24 
When ≥3 studies were available, we used the Duval and Tweedie nonparametric trim-and-fill 
method to account for potential publication bias. Based on the assumption that the effect sizes of all 
the studies are normally distributed around the center of a funnel plot, in the event of asymmetries, 
this procedure adjusts for the potential effect of unpublished (trimmed) studies.24   
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RESULTS 
The search identified 4,268 non-duplicated, potentially eligible studies. After excluding 4,229 
papers on the grounds of a review of their titles and abstracts, 39 full-text articles were examined. 
Of the full texts, 30 were excluded (mainly being cross-sectional studies) and 9 articles 25–33 were 
finally included in our meta-analysis (Supplementary Material S1).  
 
Study and patient characteristics 
As reported in Table 1, the 9 studies 25–33 followed-up 28,258 older participants for a median 
follow-up period of 7.3 (range: 2-11) years in which 2,863 participants (=10.1% of the baseline 
population) developed diabetes.  
The mean age of the participants was 67.7±4.3 years and the majority were women (64%).  All the 
studies were done among community-dwellers and mainly in Europe (studies=4) and North 
America (studies=4).  
 
As reported in Table 1, the majority of the studies used radioimmunoassay (RIA) method for 
measuring 25OHD, whilst only one 29 chemiluminescence that is considered the gold standard for 
assessing serum 25OHD levels.19 Regarding the diagnosis of diabetes, two studies 30,32 used only 
self-reported information. Other studies used self-reported information, but with a final adjudication 
by a specialist in one study25, with a value of FPG over 126 mg/d in another onel27, and with use of 
anti-diabetic medications in a third study.29 Two studies used a value of HbA1c over 6.5% for the 
diagnosis of type 2 diabetes26,31, one only a value of FPG over 126 mg/dl28 and finally one33 all the 
criteria suggested by the American Diabetes Association. 20 
 
The quality of the studies was generally of moderate quality as shown by the median eNOS values 
(median=7; range: 5-9) (Table 1).  
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Unadjusted findings regarding lower 25OHD levels and diabetes  
As shown in Figure 1, 568 older participants from 5,366 with lower vs. 752/8,197 with higher 
serum 25OHD levels (=10.6% vs. 9.2%) had a diagnosis of diabetes during follow-up period. 
Lower 25OHD levels at baseline were associated with a higher risk developing diabetes compared 
to older people with higher 25OHD levels (6 studies 25,28,30–33; n=13,563 ; RR=1.31; 95%CI: 1.11-
1.54; p=0.001; I2=37%).  
 
No publication bias was found (Egger’s test=-0.28; p=0.82) and the trim and fill analysis did not 
change our results.  
 
Adjusted analyses regarding lower 25OHD levels and diabetes 
Figure 2 shows the association between lower serum 25OHD levels at the baseline and the onset of 
diabetes at follow-up after adjusting for potential confounders. The median number of adjustments 
in the multivariate analyses was 11 (range: 4-17), with all the studies including adiposity estimates, 
as shown in Table 1.  
In the nine studies25–33 included (n=28,258) older participants, we observed that lower 25OHD 
levels at the baseline increased the risk of future diabetes of 17% (HR=1.17; 95%CI: 1.03-1.33; 
p=0.02; I2=0%). Publication bias was not present (Egger’s test=-0.34; p=0.58) and the trim and fill 
analysis did not change our findings.  
 
Meta-regression analysis 
Among the outcomes included in our analyses, no one was affected by high heterogeneity and so 
meta-regression analyses were run.  
 
 
DISCUSSION 
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In this meta-analysis including a total of 9 longitudinal studies and 28,258 older participants, we 
found evidence that hypovitaminosis D at the baseline was associated with incident diabetes at 
follow-up, also after adjusting for potential confounders.   
 
It is noteworthy that on their own, none of the longitudinal studies reported a significant association 
between hypovitaminosis D at baseline and incident diabetes after adjusting for the presence of 
potential confounders. On the contrary, when we merged the data in a meta-analysis considering a 
median of 11 potential confounders the presence of hypovitaminosis D at baseline increased the risk 
of diabetes at follow-up by 17%. Altogether these findings suggest that hypovitaminosis D in older 
adults may be a potential risk factor for diabetes.  
 
Previous literature, on the contrary, has suggested that hypovitaminosis D is not associated with the 
onset of diabetes in older adults, which may be due to a number of reasons. First, we could 
hypothesize that hypovitaminosis D may be a stronger predictor of mortality than diabetes in older 
people, as shown by a number of papers on this issue.34–37 Consequently, one hypothesis is that 
subjects with low serum 25OHD may die before developing diabetes. This hypothesis is somewhat 
reinforced by our meta-analysis suggesting that probably single studies do not have sufficient power 
to detect the association between hypovitaminosis D and diabetes, potentially due to the competitive 
risk of mortality. Second, several conditions are commonly associated with both hypovitaminosis D 
and/or diabetes. In the elderly, adiposity seems to be the most important in explaining why low 
25OHD levels are not associated with diabetes in older people.13 This hypothesis is supported by 
some of the previously-mentioned studies, which found that the significant association identified 
between poor vitamin D status and diabetes disappeared after controlling for BMI or other adiposity 
measures.28,30 Altogether our findings are in agreement with the two previous meta-analyses16,38 in 
the general population including adults of all ages. Thus, our meta-analysis confirms for the first 
time that hypovitaminosis D is associated with diabetes in the elderly.  
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Our findings open the question whether or not supplementation with vitamin D could prevent or 
slow the progression of diabetes older subjects. To the best of our knowledge, only two RCTs have 
considered vitamin D supplementation in older individuals at higher risk of diabetes.39,40 It appears 
across these studies that oral vitamin D supplementation has no effect on glucose parameters in 
participants at higher risk of diabetes.39,40 The quality of these studies seems to be adequate, the 
doses of cholecalciferol used were 700 IU/day or more, and the follow-up was long enough for any 
significant changes to emerge in the metabolic parameters investigated.41 Based also on our results, 
however, future trials are needed to confirm these findings.  
 
The findings of our study should be interpreted within its limitations. First, the observational nature 
of the studies included does not enable us to elucidate potential pathways responsible of the 
association between hypovitaminosis D and diabetes. Second, although the analyses made through 
HRs suggest a significant association between low serum 25OHD and diabetes, those made through 
adjusted ORs did not. The latter may be due to the fact only 3 study estimates were included with a 
more limited sample size. Third, the mean age of the subjects included is about 67 years. More 
focused investigations regarding very old people are so needed to better understand this association. 
Fourth, no gender separated analyses were run (due to the limited number of studies in each 
gender), even if both serum 25OHD and diabetes are usually different between men and women. 
Finally, serum 25OHD was mainly measured with RIA that seems to be a worse method to measure 
serum 25OHD than chemiluminescence.19 On the contrary, among the strengths of our work, we 
can include the large number of subjects included, the number of covariates used in the adjusted 
analyses, the follow-up period (median=7.3), long if referred to older subjects and the low 
heterogeneity found in almost all of the outcomes included.   
CONCLUSION 
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Our meta-analysis suggests that hypovitaminosis D is associated with the onset of diabetes in older 
people after adjusting for other potential risk factors. Since hypovitaminosis D is one of the most 
frequent conditions in older adults and a paucity of trials have attempted to investigate whether 
vitamin D supplementation can prevent diabetes,  future larger scale studies are needed to confirm if 
the supplementation with vitamin D could prevent diabetes’ developing in older adults.   
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LEGEND 
Figure 1. Association between lower 25 hydroxyvitamin D (25OHD) levels at baseline and 
incident diabetes.  
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Abbreviations: 25OHD = 25-Hydroxyvitamin D, CI = confidence interval 
 
 
 
 
Figure 2. Association between lower 25 hydroxyvitamin D (25OHD) levels at baseline and 
incident diabetes, after adjusting for potential confounders.  
Abbreviations: 25OHD = 25-Hydroxyvitamin D, CI = confidence interval. 
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Supplementary Figure S1. PRISMA flow-chart.  
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Table 1. Descriptive characteristics of the studies included. 
Author, 
year 
Country N  
N of 
diabete
s at 
follow 
up 
Mean 
age 
(SD)  
Percentage 
of females 
Serum 
25OHD 
(SD) 
(nmol/L) 
Follow-
up 
(years) 
Methods of 
assessment 
of serum 
25OHD 
Diagnostic 
criteria for 
diabetes 
Type of 
covariates 
Number of 
covariates 
eNOS 
Bolland A J 
et al, 2010 
New 
Zealand 
1471 29 74.0 100 
50.9  
(19.1) 
5 
RIA 
(DiaSorin, 
Stillwater, 
MN, USA) 
Self-
reported 
with a final 
adjudicatio
n by a 
specialist 
Treatment 
allocation, age, 
body weight, 
smoking status. 
4 5 
Kositsawat 
J et al, 2014 
USA 2193 477 
74.6 
(2.9) 
52 
65.8 
(28.8) 
2 
RIA 
(DiaSorin, 
Stillwater, 
MN, USA) 
Abnormal 
HbA1c 
(>6.5%) 
Age, sex, 
recruitment site, 
BMI, physical 
activity, 
vitamin D 
11 5 
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Table 1. Descriptive characteristics of the studies included. 
Author, 
year 
Country N  
N of 
diabete
s at 
follow 
up 
Mean 
age 
(SD)  
Percentage 
of females 
Serum 
25OHD 
(SD) 
(nmol/L) 
Follow-
up 
(years) 
Methods of 
assessment 
of serum 
25OHD 
Diagnostic 
criteria for 
diabetes 
Type of 
covariates 
Number of 
covariates 
eNOS 
supplementatio
n, 
multivitaminic 
use, season, 
PTH, race, 
diabetes status 
at follow-up. 
Napoli N et 
al, 2016 
USA 1939 139 
73.3 
(5.7) 
0 
65.25 
(20.8) 
6.4 
Liquid 
chromatogra
phy tandem 
mass 
FPG >126 
mg/dl,  
self- 
reported 
Age, site, race, 
season, BMI, 
calcium intake 
6 7 
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Table 1. Descriptive characteristics of the studies included. 
Author, 
year 
Country N  
N of 
diabete
s at 
follow 
up 
Mean 
age 
(SD)  
Percentage 
of females 
Serum 
25OHD 
(SD) 
(nmol/L) 
Follow-
up 
(years) 
Methods of 
assessment 
of serum 
25OHD 
Diagnostic 
criteria for 
diabetes 
Type of 
covariates 
Number of 
covariates 
eNOS 
spectrometry 
(thermofishe
r Scientific, 
franklin, 
MA, USA) 
Pilz S et al, 
2012 
Netherla
nds 
351 45 
67.8 
(5.7) 
61 
56.7 
(18.8) 
7.5 
RIA 
(DiaSorin, 
Stillwater, 
MN, USA) 
FPG >126 
mg/dl 
Fasting glucose, 
age, sex, BMI, 
HDL, TG, 
hypertension, 
physical 
activity level, 
11 7 
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Table 1. Descriptive characteristics of the studies included. 
Author, 
year 
Country N  
N of 
diabete
s at 
follow 
up 
Mean 
age 
(SD)  
Percentage 
of females 
Serum 
25OHD 
(SD) 
(nmol/L) 
Follow-
up 
(years) 
Methods of 
assessment 
of serum 
25OHD 
Diagnostic 
criteria for 
diabetes 
Type of 
covariates 
Number of 
covariates 
eNOS 
season, PTH, 
eGFR 
Robinson G 
et al, 2011 
USA 5140 317 66.0 100 
 
7.3 
DiasORIN 
liaison 
CHEMILU
MINESCEN
CE 
METHOD 
(DiaSorin, 
Stillwater, 
MN) 
Self -
reported, 
drugs 
Age, ethnicity, 
latitude, season, 
WHI study 
indicators, 
BMI, 
hypertension, 
fiber intake, 
magnesium 
intake, physical 
10 7 
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Table 1. Descriptive characteristics of the studies included. 
Author, 
year 
Country N  
N of 
diabete
s at 
follow 
up 
Mean 
age 
(SD)  
Percentage 
of females 
Serum 
25OHD 
(SD) 
(nmol/L) 
Follow-
up 
(years) 
Methods of 
assessment 
of serum 
25OHD 
Diagnostic 
criteria for 
diabetes 
Type of 
covariates 
Number of 
covariates 
eNOS 
activity level 
Schafer AL 
et al, 2014 
USA 5463 320 76.5 100 
57.4 
(27.2) 
8.6 
liquid 
chromatogra
phy tandem 
mass 
spectrometry 
(thermofishe
r Scientific, 
franklin, 
MA, USA) 
Self -
reported 
Age, clinic site, 
BMI, 
hypertension, 
self-reported 
health 
5 6 
Shottker B Germany 7791 829 62.0 58 46.1 8 RIA HbA1c > Age, sex, 15 8 
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Table 1. Descriptive characteristics of the studies included. 
Author, 
year 
Country N  
N of 
diabete
s at 
follow 
up 
Mean 
age 
(SD)  
Percentage 
of females 
Serum 
25OHD 
(SD) 
(nmol/L) 
Follow-
up 
(years) 
Methods of 
assessment 
of serum 
25OHD 
Diagnostic 
criteria for 
diabetes 
Type of 
covariates 
Number of 
covariates 
eNOS 
et al, 2012 (3.3) (9.2) (DiaSorin, 
Stillwater, 
MN, USA) 
6.5% season, 
multivitamin 
supplementatio
n, frequent fish 
consumption, 
BMI, HbA1c, 
family history 
of diabetes, 
education, 
physical 
activity, 
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Table 1. Descriptive characteristics of the studies included. 
Author, 
year 
Country N  
N of 
diabete
s at 
follow 
up 
Mean 
age 
(SD)  
Percentage 
of females 
Serum 
25OHD 
(SD) 
(nmol/L) 
Follow-
up 
(years) 
Methods of 
assessment 
of serum 
25OHD 
Diagnostic 
criteria for 
diabetes 
Type of 
covariates 
Number of 
covariates 
eNOS 
smoking, 
hypertension, 
renal 
dysfunction, 
CRP, fasting 
TG 
Thorand B 
et al,2011 
Germany 1683 416 NA 47 
 
11 
Enzyme 
immunoasse
y IDA, 
Frankfurt, 
Germany 
Self- 
reported 
Age, sex, 
survey, season, 
BMI, smoking, 
alcohol use, 
physical 
17 6 
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Table 1. Descriptive characteristics of the studies included. 
Author, 
year 
Country N  
N of 
diabete
s at 
follow 
up 
Mean 
age 
(SD)  
Percentage 
of females 
Serum 
25OHD 
(SD) 
(nmol/L) 
Follow-
up 
(years) 
Methods of 
assessment 
of serum 
25OHD 
Diagnostic 
criteria for 
diabetes 
Type of 
covariates 
Number of 
covariates 
eNOS 
activity, 
systolic BP, 
total 
cholesterol/HD
L, family 
history of 
diabetes, CRP, 
IL6, ICAM-1, 
IFN-alpha 
inducible 
protein, 
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Table 1. Descriptive characteristics of the studies included. 
Author, 
year 
Country N  
N of 
diabete
s at 
follow 
up 
Mean 
age 
(SD)  
Percentage 
of females 
Serum 
25OHD 
(SD) 
(nmol/L) 
Follow-
up 
(years) 
Methods of 
assessment 
of serum 
25OHD 
Diagnostic 
criteria for 
diabetes 
Type of 
covariates 
Number of 
covariates 
eNOS 
markers of 
inflammation, 
waist to hip 
ratio. 
Veronese N 
et al, 2014 
Italy 2227 291 
76.1 
(7.8) 
59 
80.1 
(54.7) 
4.4 
RIA 
(DiaSorin, 
Stillwater, 
MN, USA) 
FPG > 126 
mg/dl or 
HbA1c> 
6.5% or 
use of 
medication
s 
Age, gender, 
waist, 
hypertension, 
education, 
monthly 
income, 
smoking, 
11 8 
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Table 1. Descriptive characteristics of the studies included. 
Author, 
year 
Country N  
N of 
diabete
s at 
follow 
up 
Mean 
age 
(SD)  
Percentage 
of females 
Serum 
25OHD 
(SD) 
(nmol/L) 
Follow-
up 
(years) 
Methods of 
assessment 
of serum 
25OHD 
Diagnostic 
criteria for 
diabetes 
Type of 
covariates 
Number of 
covariates 
eNOS 
eGFR, FPG, 
HbA1c, total 
cholesterol 
Total 
(weighted 
for the 
sample 
size) 
 
28,258 2,863 
67.7 
(4.3) 
64% 
56.8 
(22.4) 
Median
=7.3 
(range:  
2-11) 
years 
5 studies: 
RIA;  
2 studies: 
mass 
spectrometr
y; 1 study: 
ELISA;  
1 study: 
  
Median=11 
(range: 
4-17) 
Media
n=7 
(range
: 5-9) 
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Table 1. Descriptive characteristics of the studies included. 
Author, 
year 
Country N  
N of 
diabete
s at 
follow 
up 
Mean 
age 
(SD)  
Percentage 
of females 
Serum 
25OHD 
(SD) 
(nmol/L) 
Follow-
up 
(years) 
Methods of 
assessment 
of serum 
25OHD 
Diagnostic 
criteria for 
diabetes 
Type of 
covariates 
Number of 
covariates 
eNOS 
chemilumin
escence 
 
Abbreviations: SD = standard deviation, 25OHD = 25-Hydroxyvitamin D, RIA = radioimmunoassay, HbA1c = glycated hemoglobin, BMI = body 
mass index, PTH = parathyroid hormone, FPG = fasting plasma glucose, HDL = high-density lipoproteins, TG = triglyceride, eGFR = glomerular 
filtration rate, CRP = C-reactive protein, Systolic BP = systolic blood pressure (BP), IL6 = Interleukin 6, ICAM 1 = Intercellular Adhesion 
Molecule 1, IFN-alpha = interferons-alpha, ELISA = enzyme-linked immunosorbent assay. 
 
